The treatment of osteoarthritis with new injectable cells may be successful.

Published Date: 26 Apr 2023

Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a promising injectable cell therapy for osteoarthritis that not only lowers inflammation but also regenerates articular cartilage.

Read Full News

Latest News

PT Beats CBT for First-Line Low Back Pain Treatment

Findings of a real-world study confirm guidelines that recommend physical therapy as first-line treatment; it has a slight edge over cognitive-behavioral therapy.

Do Palindromic Flares Indicate Future Arthritis Joint Sites?

Palindromic rheumatism often begins with hand and shoulder involvement, and patients who progress to persistent inflammatory arthritis develop it in joints affected by prior palindromic flares.

Prescribing Walks Wisely in Low Back Pain

Individualized walking programs can reduce recurrent, disabling low back pain, but clinicians should screen for lower extremity biomechanical vulnerabilities and favor low impact options when needed.

Winter Sports and Lower Limb Motor Disability

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

Early Sports Specialization Affects Hip Development

New research suggests that kids who focus on one sport are more likely to experience physical problems later, hip injury in particular.

Ascendis Wins US Approval for Therapy for Children With Dwarfism

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy ⁠for children with a rare genetic disorder that causes dwarfism, the company...

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Latest News

Findings of a real-world study confirm guidelines that recommend physical therapy as first-line treatment; it has a slight edge over cognitive-behavioral therapy.

Palindromic rheumatism often begins with hand and shoulder involvement, and patients who progress to persistent inflammatory arthritis develop it in joints affected by prior palindromic flares.

Individualized walking programs can reduce recurrent, disabling low back pain, but clinicians should screen for lower extremity biomechanical vulnerabilities and favor low impact options when needed.

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

New research suggests that kids who focus on one sport are more likely to experience physical problems later, hip injury in particular.

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy ⁠for children with a rare genetic disorder that causes dwarfism, the company...

News All Time

Arthritis pain rising: How state policies matter

New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.

Customizable finger brace toggles between stiff and flexible for easier recovery

A friend's struggles with arthritis and the finger braces used to manage it inspired research by a Carnegie Mellon University student that could make it easier for patients to follow rehabilitation plans, speed up recovery ...

AI predicts future X-rays to help osteoarthritis patients and their doctors see what's coming

An AI system that can predict what a patient's knee X-ray will look like a year in the future could transform how millions of people with osteoarthritis understand and manage their condition, according to research by the ...

Joint pain or osteoarthritis? Exercise could be the first line of treatment

Stiff knees, aching hips and the slow grind of chronic joint pain are often accepted as an unavoidable part of getting older. But while osteoarthritis is the world's most common joint disease, experts say the way we treat ...

Study finds tailored exercise program feasible for adults over 80 with osteoarthritis

A new NDORMS study has found that a tailored exercise program for people aged 80 years and older with hip and/or knee osteoarthritis and other long term health conditions is both practical and acceptable, paving the way for ...

New treatment for psoriatic arthritis shows promising results in early trial

A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in an international clinical trial of more than 200 patients worldwide.

Seven-year study reveals rheumatoid arthritis begins long before symptoms, opening door to prevention 

Scientists have discovered that rheumatoid arthritis (RA) doesn't start when the pain begins. It silently starts years earlier. RA is a debilitating autoimmune disease that causes painful joint inflammation and damage. The ...

Analysis isolates population aging as primary driver of musculoskeletal disorders

Novel research shows that in approximately one third of countries and territories worldwide, population aging was the largest contributor to the growing burden of musculoskeletal disorders from 1990 to 2021.

Self-guided online program improves quality of life in rheumatoid arthritis, psoriatic arthritis and lupus

Patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus frequently face anxiety and depression along with chronic physical symptoms. Reported rates of depression range from 15% to 24% and ...

Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual ...

Current research may open doors to new treatments for children with juvenile dermatomyositis

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).

Squishy 'smart cartilage' could target arthritis pain as soon as flareups begin

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.

Immune aging may be a driver of rheumatoid arthritis rather than a consequence

Features of immune system aging can be detected in the earliest stages of rheumatoid arthritis (RA), even before clinical diagnosis, a new study has found which provides at-risk individuals with hope for early intervention.

Common arthritis drug found to lower blood pressure and risk of heart disease

Methotrexate, a common medication used to treat rheumatoid arthritis, has a newly recognized useful secondary effect of lowering blood pressure and potentially reduces the risk of heart disease in people with this condition.

Noisy knees not an early arthritis sign, says new study

Knee crepitus, the sound of cracking or grinding in the knee joint, is very common across all age groups.

Q&A: These genetic insights into rheumatoid arthritis could help design better treatments

People with rheumatoid arthritis (RA) often have trouble getting out of bed in the morning, let alone getting to the rheumatologist for a checkup or participating in a research study. This makes a deeper understanding of ...

Recommended News For You

Detecting pancreatic cancer through changes in body composition and metabolism

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

Treating advanced prostate cancer

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

Recommended Articles For You

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits 

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma  

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer 

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Single-dose radiation before surgery can eradicate breast cancer

2.

Never in a million years did I think I'd have to limit my chemotherapy.

3.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

4.

Virtual Reality Travel Reduces Cancer Pain.

5.

The Truth About Apple AirPods

1.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

2.

A Comprehensive Guide To Understanding Plasma Osmolality

3.

The Rise of Immunotherapy: New Advances in Cancer Treatment

4.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

5.

Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot